Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Ghafouri-Fard, Soudeha | Sohrabi, Behnoushb | Hussen, Bashdar Mahmudc | Mehravaran, Elhamd | Jamali, Elenae | Arsang-Jang, Shahramf | Fathi, Mohadesehg | Taheri, Mohammadh; | Samsami, Majidi;
Affiliations: [a] Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [b] Department of Biology, Faculty of Sciences, Arak University, Arak, Iran | [c] Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Kurdistan Region, Iraq | [d] Motamed Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran | [e] Department of Pathology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [f] Cancer Gene Therapy Research Center, Zanjan University of Medical Science, Zanjan, Iran | [g] Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [h] Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [i] Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Correspondence: [*] Corresponding authors: Mohammad Taheri, Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: [email protected]. Majid Samsami, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: [email protected]
Abstract: TP53 encodes a major tumor suppressor protein which blocks carcinogenesis process in a variety of tissues including breast tissue. Expression and function of this gene is regulated by a number of long non-coding RNAs (lncRNAs) among them are PANDA, MEG3 and CASC2. We measured expression of TP53 and these transcripts in a cohort of Iranian breast cancer patients. Expression levels of TP53, MEG3, CASC2 and PANDA were significantly lower in tumoral samples compared with non-tumoral samples (Posterior mean differences = −4.26, −1.66, −5.98 and −3.13, respectively; P values < 0.0001). Expression of CASC2 was higher in Her2 1+ cases compared with Her2 negative cases (Beta = 1.85, P value = 0.037). Expression levels of MEG3 and TP53 were lower in grade 2 samples compared with grade 1 (Beta = −1.86, P value = 0.006 and Beta = −2.24, P value = 0.003, respectively). There was no other significant association between expression of genes and clinical variables. CASC2 had the best performance among these genes with area under curve value of 0.78 and sensitivity and specificity values of 56.33% and 88.73%, respectively (P value < 0.0001). The current investigation supports the role of TP53-related lncRNAs in the pathogenesis of breast cancer.
Keywords: TP53, lncRNA, PANDA , MEG3 , CASC2
DOI: 10.3233/BD-210069
Journal: Breast Disease, vol. 41, no. 1, pp. 137-143, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]